Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Rhabdomyosarcoma, Embryonal 1Rhabdomyosarcoma, Alveolar 1Rhabdomyosarcoma 1

Interventions

Specimen Handling 71Magnetic Resonance Spectroscopy 55Biopsy 43pembrolizumab 25Carboplatin 25Radiation 24Radiotherapy 23Cyclophosphamide 23Nivolumab 21Paclitaxel 20Cisplatin 20olaparib 18Etoposide 18Doxorubicin 17X-Rays 16Vincristine 16Taxes 15Immunoglobulin G 15Disulfides 15Radiotherapy, Intensity-Modulated 14Leucovorin 14Dexamethasone 14Cytarabine 14Bevacizumab 14durvalumab 13Prednisone 13Platinum 131,2-diaminocyclohexaneplatinum II citrate 13Methotrexate 11Ipilimumab 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Vinorelbine × 30 days × Clear all
NCT02567435 2026-05-27

Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
325 enrolled 14 charts
Sarcoma

Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡